<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03855579</url>
  </required_header>
  <id_info>
    <org_study_id>Levosimendan, Milrinone, CABG</org_study_id>
    <nct_id>NCT03855579</nct_id>
  </id_info>
  <brief_title>Levosimendan Versus Milrinone in Off Pump CABG Surgery</brief_title>
  <official_title>Levosimendan Versus Milrinone to Support Hemodynamics During Off Pump Coronary Artery Bypass Grafting Surgery in Patients With Poor Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of Levosimendan versus Milrinone in supporting hemodynamics during
      off-pump coronary artery bypass grafting surgery in patients with low ejection fraction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The major challenge during off-pump coronary artery bypass graft surgery is to maintain
      optimum hemodynamics by optimizing the intravascular volume and by using some inotropes.
      However, conventional inotropes such as betaâ€‘agonists are associated with tachycardia and
      arrhythmia which increase myocardial oxygen demand.

      Levosimendan is an inodilator which exerts its positive inotropic effect by enhancing the
      sensitivity of troponin C to calcium without increasing intracellular calcium concentration.
      Levosimendan also decreases the systemic vascular resistance, so, it increases the cardiac
      output without increasing myocardial oxygen consumption.

      This study aims to compare the efficacy of Levosimendan versus Milrinone in supporting
      hemodynamics during off-pump coronary artery bypass grafting surgery in patients with low
      ejection fraction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2019</start_date>
  <completion_date type="Anticipated">September 10, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 10, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean blood pressure</measure>
    <time_frame>Intraoperative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Consumption of other inotropes</measure>
    <time_frame>Intraoperative</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hemodynamics</condition>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraoperative infusion of Levosimendan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Milrinone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraoperative infusion of Milrinone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>Intraoperative infusion of Levosimendan</description>
    <arm_group_label>Levosimendan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milrinone</intervention_name>
    <description>Intraoperative infusion of Milrinone</description>
    <arm_group_label>Milrinone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective off-pump coronary artery bypass grafting surgery.

          -  ejection fraction &lt; 50%

        Exclusion Criteria:

          -  Patients with severe renal impairment or renal failure.

          -  Patients on mechanical support (intra-aortic balloon pump)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hany M. Osman, M.D.</last_name>
    <phone>+201002414591</phone>
    <phone_ext>N.</phone_ext>
    <email>hanymeo@aun.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fatma Mohamed, M.D.</last_name>
    <email>fatmanabil2012@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assiut University</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hany M. Osman, M.D.</last_name>
      <phone>+201002414591</phone>
      <email>hanymeo@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Fatma N. Mohamed, M.D.</last_name>
      <phone>+201003633992</phone>
      <email>fatmanabil2012@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hany M. Osman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fatma N. Mohamed, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed Anwar, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 24, 2019</study_first_submitted>
  <study_first_submitted_qc>February 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2019</study_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Hany Mostafa Esmaeil Osman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Levosimendan</keyword>
  <keyword>Milrinone</keyword>
  <keyword>Off-pump</keyword>
  <keyword>Coronary</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
    <mesh_term>Milrinone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

